Published on October 15, 2013 at 1:10 PM
A new range of animal-free and endotoxin-free growth factors and cytokines, tailored to stem cell research, has been launched by AMSBIO – a leading supplier of recombinant proteins.
The success of stem cell research depends on the development of optimal cell culture systems. Both expansion and differentiation of stem cells is highly reliant on growth factor and cytokine supplements, with the activity and purity of these recombinants being critical to successful research and clinical applications. Despite recognised limitations - E. coli and mammalian cells remain the dominant expression systems for commercial recombinant protein production. Although significant improvements in manufacture have been made, both systems present a risk of unwanted contamination from pathogens and endotoxins.
Endotoxins are an unavoidable by-product of commercial E.coli recombinant protein manufacture, including those produced for stem cell research. The stability of endotoxins and affinity for proteins make it almost impossible to completely remove endotoxins. As a result the currently accepted safety limit of endotoxin impurities in recombinant protein products is below < 0.1 ng/µg endotoxin or 1 EU/mg. While pathogen risks are well documented, there are a growing number of reports that demonstrate endotoxin concentrations as low as 2 pg/ml can result in significant biological responses.
To address the growing body of evidence suggesting accepted levels of endotoxin contamination may significantly compromise stem cell maintenance and differentiation – AMSBIO has launched its new range of animal-free and endotoxin-free growth factors and cytokines. These new recombinant growth factors and cytokines are produced in a plant based expression system that utilizes barley seed to eliminate the risks and limitations associated with these traditional expression systems.
For further information on this growing range of recombinant proteins please visit http://www.amsbio.com/animal-endotoxin-free-recombinants.aspx or contact AMSBIO now on +44-1235-828200 / +1-949-768-8365 or email email@example.com.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading company contributing to the acceleration of discovery through the provision of cutting-edge life science technology products and services for research and development in the medical, nutrition, cosmetics and energy industries. The AMSBIO range includes specialist antibodies, peptides and recombinant proteins. In addition the company is able to draw upon in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. Widely acknowledged as experts in cell culture, AMSBIO partners with clients in tailoring cell systems to enhance screening outcomes and eventual prognosis. With a range of molecular detection reagents, and a significant Biorepository the company can also provide tissue DNA, RNA, protein and microarray products. Key research areas for these products include: Oncology, Regenerative Medicine, Environmental Analysis, Cytotoxicity Screening, Glycomics and Stem Cell Biology.